Regeneron Pharmaceuticals Officer Andrew J. Murphy Files Form 144 to Sell $3.2M in Common Stock
REGENERON PHARMACEUTICALS, INC.
Subscribe to track REGN
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# Form 144 Notice: Regeneron Pharmaceuticals, Inc. ($REGN)
**Insider:** Andrew J. Murphy (Officer)
**Filing Date:** October 14, 2026
**Proposed Sale Shares:** 4,147
**Approximate Market Value:** $3,204,379.85 (~$772.70/share)
**Broker:** UBS Financial Services, Inc.
**10b5-1 Plan Adoption Date:** May 7, 2026
**Nature of Acquisition:** Exercise of Stock Options (Net Exercise on 10/13/2026)
Comprehensive Analysis
Executive Summary
On October 14, 2026, Andrew J. Murphy, an Officer of Regeneron Pharmaceuticals, Inc. ($REGN), filed Form 144 indicating an intent to sell 4,147 shares of Common Stock through UBS Financial Services, Inc., with an aggregate market value of approximately $3.20 million.
Transaction Details
- Shares Proposed for Sale: 4,147 shares
- Aggregate Market Value: $3,204,379.85 (~$772.70 per share)
- Shares Outstanding: 101,137,842 shares (proposed sale represents ~0.004% of outstanding shares)
- Acquisition Origin: Acquired via net exercise of stock options on October 13, 2026 (4,174 shares acquired from the issuer).
- Rule 10b5-1 Trading Plan: The transaction is executed pursuant to a pre-scheduled Rule 10b5-1 trading plan adopted on May 7, 2026.
Market & Trading Significance
The trading significance is assessed as Low. While the aggregate dollar amount ($3.2M) is substantial, the sale represents a routine liquidation following an option exercise executed under a Rule 10b5-1 trading plan adopted more than five months earlier. Consequently, this transaction does not signal unexpected discretionary selling or shifts in insider sentiment.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.